Wall Street analyst estimates for Immix Biopharma, Inc. (IMMX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors.
Valuation Ratios
| Price / Book | 3.29 |
| EV / EBITDA | -13.21 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $583162 | $248149 | $126527 | $4.2M | $8.7M | $11.3M | $16.3M |
| Selling, General & Admin | $259337 | $205703 | $1.2M | $4.0M | $7.4M | $11.4M | $13.7M |
| Operating Expenses | $842499 | $453852 | $1.4M | $8.2M | $16.1M | $22.7M | $30.0M |
| Operating Income | -$842499 | -$453852 | -$1.4M | -$8.2M | -$16.1M | -$22.7M | -$30.0M |
| EBITDA | -$841417 | -$451531 | -$24.2M | -$8.2M | -$15.6M | -$21.5M | -$29.6M |
| Interest Expense | $109984 | $101976 | $179853 | $497 | 0 | 0 | 0 |
| Pre-tax Income | -$952259 | -$1.1M | -$24.4M | -$8.2M | -$15.6M | -$21.7M | -$29.4M |
| Income Tax | $20552 | $17547 | $6013 | $10268 | $26415 | $41037 | $37724 |
| Net Income | -$972811 | -$1.1M | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
| EPS | $-0.29 | $-0.15 | $-6.64 | $-0.59 | $-0.89 | $-0.76 | $-0.89 |
| EPS (Diluted) | $-0.29 | $-0.15 | $-6.64 | $-0.59 | $-0.89 | $-0.76 | $-0.89 |
| Shares Outstanding (Diluted) | $3.4M | $7.8M | $3.7M | $13.9M | $17.3M | $28.3M | $33.0M |
Price
| Price | $11.92 |
| Market Cap | $648M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATOS · COYA · MGNX · ONCY · ORMP · PLRX · SRZN
Explore sector: Healthcare · Biotechnology
More sections of IMMX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks